-
平臺編號：bio-69492
-
國際編號：CRL-2277?
-
細胞信息： BC-3
-
規(guī)格：Frozen
-
用途：ATCC原裝細胞
-
服務費用：
加載中…… - 訂購
-
注意事項：僅用于科學研究或者工業(yè)應用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準）
BC-3
生長狀態(tài)：懸浮生長
運輸方式：凍存運輸
ATCC Number：CRL-2277?
相關疾病：淋巴瘤
年限：85 years
數(shù)量：大量
細胞類型：B淋巴細胞
是否是腫瘤細胞：1
物種來源：人
細胞形態(tài)：淋巴樣
規(guī)格：48T Designations: BC-3
Depositors: ?Cornell Res. Fndn., Inc.
Biosafety Level:2 [Cells contain Kaposi's sarcoma-associated herpesvirus genome ]
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Homo sapiens
Morphology:lymphoblast
Source: Disease: lymphoma
Cell Type: B lymphocyte;
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications:transfection host (Roche Transfection Reagents )
Antigen Expression:CD30 +; CD38 +; CD45 +; CD 54 +; CD71 +; HLA-DR +; EMA + (epithelial membrane antigen); CD2 -; CD3 -; CD4 -; CD5 -, CD8 -; CD19 -; CD20 -; CD21 -; CD22 -
DNA Profile (STR):Amelogenin: X
CSF1PO: 11,12
D13S317: 11
D16S539: 12
D5S818: 11,12
D7S820: 10,12
THO1: 6,9
TPOX: 8,11
vWA: 14,18
Age: 85 years
Gender: male
Ethnicity: Caucasian
Comments:BC-3 is a primary effusion lymphoma cell line originated in 1995 by Leandros Arvanitakis and Ethel Cesarman.
The cells were established from pleural effusion from a human immunodeficiency virus (HIV) negative patient diagnosed with primary effusion (body cavity based) lymphoma (PEL).
The BC-3 cell line contains the viral genome for Kaposi's sarcoma-associated herpesvirus (KSHV, provisionally designated HHV-8).
KSHV is a recently identified and partially uncharacterized virus.
BC-3 cells are negative for both HIV and Epstein-Barr virus (EBV).
They are also reported to be negative for herpes simplex virus 1 & 2 (HSV-1 and HSV-2) and cytomegalovirus (CMV).
The BC-3 cell line allows in vitro culture of KSHV viral genomes in the absence of EBV.
It is ideal for the isolation and study of KSHV.
BC-3 has an intact KSHV genome of about 170 kb both in the cell line and in the viral isolate.
The cells do not express B-cell lineage restricted antigens or kappa or lambda immunoglobulin light chains) or T-cell lineage-restricted antigens.
The cells do express activation antigens.
Propagation: ATCC complete growth medium: RPMI 1640 medium, 80%; fetal bovine serum, 20%
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 5 X 10 exp5 cells/ml and maintain between 5 X 10 exp5 and 2 X 10 exp6 cells/ml.
Preservation: Culture medium, 95%; DMSO, 5%
References: 23359: Arvanitakis L, et al. Establishment and characterization of a primary effusion (body cavity- based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88: 2648-2654, 1996. PubMed: 8839859
39036: Cesarman E, et al. KSHV positive cell lines. US Patent 5,908,773 dated Jun 1 1999
運輸方式：凍存運輸
ATCC Number：CRL-2277?
相關疾病：淋巴瘤
年限：85 years
數(shù)量：大量
細胞類型：B淋巴細胞
是否是腫瘤細胞：1
物種來源：人
細胞形態(tài)：淋巴樣
規(guī)格：48T Designations: BC-3
Depositors: ?Cornell Res. Fndn., Inc.
Biosafety Level:2 [Cells contain Kaposi's sarcoma-associated herpesvirus genome ]
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Homo sapiens
Morphology:lymphoblast
Source: Disease: lymphoma
Cell Type: B lymphocyte;
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications:transfection host (Roche Transfection Reagents )
Antigen Expression:CD30 +; CD38 +; CD45 +; CD 54 +; CD71 +; HLA-DR +; EMA + (epithelial membrane antigen); CD2 -; CD3 -; CD4 -; CD5 -, CD8 -; CD19 -; CD20 -; CD21 -; CD22 -
DNA Profile (STR):Amelogenin: X
CSF1PO: 11,12
D13S317: 11
D16S539: 12
D5S818: 11,12
D7S820: 10,12
THO1: 6,9
TPOX: 8,11
vWA: 14,18
Age: 85 years
Gender: male
Ethnicity: Caucasian
Comments:BC-3 is a primary effusion lymphoma cell line originated in 1995 by Leandros Arvanitakis and Ethel Cesarman.
The cells were established from pleural effusion from a human immunodeficiency virus (HIV) negative patient diagnosed with primary effusion (body cavity based) lymphoma (PEL).
The BC-3 cell line contains the viral genome for Kaposi's sarcoma-associated herpesvirus (KSHV, provisionally designated HHV-8).
KSHV is a recently identified and partially uncharacterized virus.
BC-3 cells are negative for both HIV and Epstein-Barr virus (EBV).
They are also reported to be negative for herpes simplex virus 1 & 2 (HSV-1 and HSV-2) and cytomegalovirus (CMV).
The BC-3 cell line allows in vitro culture of KSHV viral genomes in the absence of EBV.
It is ideal for the isolation and study of KSHV.
BC-3 has an intact KSHV genome of about 170 kb both in the cell line and in the viral isolate.
The cells do not express B-cell lineage restricted antigens or kappa or lambda immunoglobulin light chains) or T-cell lineage-restricted antigens.
The cells do express activation antigens.
Propagation: ATCC complete growth medium: RPMI 1640 medium, 80%; fetal bovine serum, 20%
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 5 X 10 exp5 cells/ml and maintain between 5 X 10 exp5 and 2 X 10 exp6 cells/ml.
Preservation: Culture medium, 95%; DMSO, 5%
References: 23359: Arvanitakis L, et al. Establishment and characterization of a primary effusion (body cavity- based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88: 2648-2654, 1996. PubMed: 8839859
39036: Cesarman E, et al. KSHV positive cell lines. US Patent 5,908,773 dated Jun 1 1999
